China Sees Flurry Of Activity On Avastin

Innovent’s Biosimilar Bevacizumab Approved As Bio-Thera And Henlius Advance

An approval for Innovent’s bevacizumab biosimilar has been granted in China, while other potential rivals to Avastin in the region have hit development milestones.

Eye_China_Flag
China has seen an approval for one bevacizumab biosimilar, with others in the pipeline • Source: Shutterstock

More from Biosimilars

More from Products